A genome-wide association study identifies new loci for ACE activity: Potential implications for response to ACE inhibitor

Pharmacogenomics Journal

Volumn 10, Issue 6, 2010, Pages 537-544

  Chung, C M ^a   Wang, R Y ^b   Chen, J W ^a,c   Fann, C S J ^a,d   Leu, H B ^c   Ho, H Y ^e   Ting, C T ^e   Lin, T H ^f,g   Sheu, S H ^f,g   Tsai, W C ^h   Chen, J H ^h   Jong, Y S ⁱ   Lin, S J ^c   Chen, Y T ^d   Pan, W H ^d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

ⁱ TAO YUAN GENERAL HOSPITAL   (Taiwan)

Author keywords

ABO; ACE; GWAS; hypertension; pharmacogenetics

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ABO GENE; ACE STRUCTURAL GENE; ADULT; ARTICLE; BLOOD GROUP ABO SYSTEM; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE; GENE MAPPING; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM;

ABO BLOOD-GROUP SYSTEM; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPERTENSION; MALE; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI;

EID: 78649328373     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.70     Document Type: Article

References (31)

1. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447: 661-678.
2. Wang TH, Wang HS. A genome-wide association study primer for clinicians. Taiwan J Obstet Gynecol 2009; 48: 89-95.
3. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007; 357: 443-453. (Pubitemid 47204873)
4. Ikram MA, Seshadri S, Bis JC, Fornage M, DeStefano AL, Aulchenko YS et al. Genomewide association studies of stroke. N Engl J Med 2009; 360: 1718-1728, NEJMoa0900094.
5. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-645.
6. Pan WH, Lynn KS, Chen CH, Wu YL, Lin CY, Chang HY. Using endophenotypes for pathway clusters to map complex disease genes. Genet Epidemiol 2006; 30: 143-154.
7. Castellon R, Hamdi HK. Demystifying the ACE polymorphism: from genetics to biology. Curr Pharm Des 2007; 13: 1191-1198.
8. Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 2002; 23: 177-183.
9. Ehlers MR, Riordan JF. Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry 1989; 28: 5311-5318.
10. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res 2006; 98: 1123-1133.
11. Rudnicki M, Mayer G. Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. Pharmacogenomics 2009; 10: 463-476.
12. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
13. Zhu X, Bouzekri N, Southam L, Cooper RS, Adeyemo A, McKenzie CA et al. Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet 2001; 68: 1139-1148.
14. Alhenc-Gelas F, Richard J, Courbon D, Warnet JM, Corvol P. Distribution of plasma angiotensin I-converting enzyme levels in healthy men: relationship to environmental and hormonal parameters. J Lab Clin Med 1991; 117: 33-39.
15. Pan WH, Hung YT, Shaw NS, Lin W, Lee SD, Chiu CF et al. Elderly Nutrition and Health Survey in Taiwan (1999-2000): research design, methodology and content. Asia Pac J Clin Nutr 2005; 14: 203-210.
16. Kasahara Y, Ashihara Y. Colorimetry of angiotensin-I converting enzyme activity in serum. Clin Chem 1981; 27: 1922-1925.
17. Wang RY, Chung CM, Fann CS, Yang HC, Chen JW, Jong YS et al. Genome-wide scan for quantitative ACE activity in Taiwan Young-Onset Hypertension study. Hum Hered 2008; 65: 85-90.
18. Blumenfeld OO, Patnaik SK. Allelic genes of blood group antigens: a source of human mutations and cSNPs documented in the Blood Group Antigen Gene Mutation Database. Hum Mutat 2004; 23: 8-16.
19. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-130.
20. Cidl K, Strelcova L, Znojil V, Vachi J. Angiotensin I-converting enzyme (ACE) polymorphism and ABO blood groups as factors codetermining plasma ACE activity. Exp Hematol 1996; 24: 790-794.
21. Takasaki S, Yamashita K, Kobata A. The sugar chain structures of ABO blood group active glycoproteins obtained from human erythrocyte membrane. J Biol Chem 1978; 253: 6086-6091.
22. Borecki IB, Elston RC, Rosenbaum PA, Srinivasan SR, Berenson GS. ABO associations with blood pressure, serum lipids and lipoproteins, and anthropometric measures. Hum Hered 1985; 35: 161-170.
23. Bezemer ID, Rosendaal FR. Predictive genetic variants for venous thrombosis: what's new? Semin Hematol 2007; 44: 85-92.
24. Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 62-69.
25. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006; 46: 1836-1844.
26. Naim HY. Human small intestinal angiotensin-converting enzyme: intracellular transport, secretion and glycosylation. Biochem J 1993; 296(Part 3): 607-615.
27. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. JAMA 1982; 248: 2004-2011.
28. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005; 111: 3374-3383.
29. Belz GG, Breithaupt K, Erb K. Review of studies on the clinical pharmacodynamics of cilazapril. J Cardiovasc Pharmacol 1994; 24(Suppl 2): S14-S19.
30. Lang RM, DiBianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA et al. First-dose effects of enalapril 2.5mg and captopril 6.25mg in patients with heart failure: a double-blind, randomized, multicenter study. The Enalapril-Captopril Investigators. Am Heart J 1994; 128: 551-556.
31. Ehret GB, Morrison AC, O'Connor AA, Grove ML, Baird L, Schwander K et al. Replication of the Wellcome Trust genome-wide association study of essential hypertension: the Family Blood Pressure Program. Eur J Hum Genet 2008; 16: 1507-1511.